This cooperativity is in accord with human prostate cancer genomic data, where TP53 alteration rate (mutation or copy number loss) is significantly higher in ETS fusion–positive samples than that in ETS fusion–negative samples (Fig. 4A) (3). The gene discussed is TP53; the disease is prostate cancer.